{'fraction_non_alphanumeric': 0.037703016241299306, 'fraction_numerical': 0.0382830626450116, 'mean_word_length': 5.55893536121673, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Investigation of beta‐glucans binding to human/mouse dectin‐1 and associated immunomodulatory effects on two monocyte/macrophage cell lines

Dectin‐1, a specific pattern recognition receptor for β‐1,3/β‐1,6‐glucans, is expressed mainly on phagocytes. Human dectin‐1 (hDectin‐1) and mouse dectin‐1 (mDectin‐1) were separately expressed on HEK293 cell surfaces for examination of the binding abilities of a synthetic particulate β‐glucan (pβG), a product extracted from Saccharomyces cerevisiae, in this study. The binding of zymosan‐FITC to hDectin‐1 and mDectin‐1 was inhibited by pβG at similar concentrations for 50% inhibition of binding (IC50). However, the kinetics of the time course and dose response to zymosan stimulation observed for U937 and J774A.1 differed. Superoxide anion production was increased in U937 but reduced in J774A.1 when cells were treated with pβG, zymosan, or laminarin, whereas ovalbumin endocytosis was enhanced in U937 and J774A.1 treated either with pβG, zymosan, laminarin, or barley‐glucan. These results indicate that the binding affinity of pβG to hDectin‐1 is similar to the binding affinity to mDectin‐1, and that stimulation by pβG as well as various forms of β‐1,3‐glucans on U937 and J774A.1 resulted in upregulation of cell activity and ovalbumin endocytosis. Additionally, other coreceptors on U937 and J774A.1 may be involved in directing different responses to superoxide anion production in these two types of cells. These results will likely contribute to further investigations on identifying the biological forms of β‐glucans capable of binding its specific receptor as the effective immunomodulators. © 2010 American Institute of Chemical Engineers Biotechnol. Prog., 2010